柳藥股份(603368.SH):擬變更公司名稱為“廣西柳藥集團股份有限公司”、證券簡稱為“柳藥集團”
格隆匯3月31日丨柳藥股份(603368.SH)公佈,2022年3月30日,廣西柳州醫藥股份有限公司召開第四屆董事會第二十一次會議,審議通過了《關於變更公司名稱、證券簡稱的議案》,並同意將議案中關於變更公司名稱事項提交公司股東大會審議。
公司中文名稱由“廣西柳州醫藥股份有限公司”變更為“廣西柳藥集團股份有限公司”(最終以登記機關核准為準)。
公司英文名稱由“Guangxi Liuzhou Pharmaceutical Co., Ltd.”變更為“Guangxi LiuYao Group Co., Ltd”(最終以登記機關核准為準)。
公司證券簡稱由“柳藥股份”變更為“柳藥集團”;證券代碼“603368”保持不變。此次變更證券簡稱事項尚需向上海證券交易所申請,並經上海證券交易所批准通過後方可實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.